Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 114-117

  Cornely, O A ^a   Maertens, J ^b   Bresnik, M ^c   Ullmann, A J ^d   Ebrahimi, R ^c   Herbrecht, R ^e  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c GILEAD SCIENCES   (United States)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Antagonism; Aspergillosis; Polyenes

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOULD; MYCOSIS; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77950363815     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp397     Document Type: Article

References (15)

1. Cornely OA, Böhme A, Buchheidt D et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94: 113-22.
2. Maertens J, Frère P, Lass-Flörl C et al. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer Suppl 2007; 5:43-8.
3. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
4. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
5. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
6. Farowski F, Vehreschild JJ, Cornely OA. Posaconazole: a next-generation triazole antifungal. Future Microbiol 2007; 2: 231-43.
7. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49 Suppl 1: 21-30.
8. Meletiadis J, Petraitis V, Petraitiene R et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006; 194: 1008-18.
9. Kirkpatrick WR, Coco BJ, Patterson TF. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2006; 50: 1567-9.
10. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37 Suppl 3: S188-224.
11. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
12. Candel FJ, Matesanz M, Mensa J. Sequential prescription of antifungals in invasive fungal infection: the importance of mechanism of action. Int J Antimicrob Agents 2008; 32 Suppl 2: S133-5.
13. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
14. Vehreschild JJ, Bohme A, Reichert D et al. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. Int J Hematol 2008; 87: 126-31.
15. Patterson TF, Boucher HW, Herbrecht R et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448-52.